Microfibril Associated Protein 4 (MFAP4) as a biomarker of emphysema

Research output: Contribution to conference without publisher/journalPosterResearchpeer-review

Abstract

Background
To enhance accuracy in evaluating prognosis and target therapy, there is a need for biomarkers in COPD. Yet, there are no reliable biomarkers that can differentiate between phenotypes of COPD.
MFAP4 is a glycoprotein, co-localized with elastin and microfibrils in elastic fibres. We hypothesized that circulating MFAP4 reflects elastin degradation and thereby emphysema in COPD patients.

Methods
Plasma levels of MFAP4 (pMFAP4) were determined by ELISA in 74 Danish COPD patients from the multicentre ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points) study. Associations between log-transformed pMFAP4 levels and clinical outcomes were assessed by multiple regression analysis. Age, gender and current smoking were included as covariates.

Results
Levels of pMFAP4 associated significantly with GOLD stages and were significantly higher in GOLD IV than in II.
LogpMFAP4 was positively correlated to percentage of low attenuation area on HRCT (LAA%) (β: 0.007, p<0.005). There was moreover a significant negative association between plasma logpMFAP4 and FEV1/FVC index (β:-0.007, p<0.05), reversibility (β:-0.6p<0.05). There was a significant interaction between gender and BMI and Fat Free Mass Index respective (FFMI), showing a significant negative association between MFAP4 and BMI (β:-0.03, p<0.01) and FFMI (β:-0.08, p<0.005) among women.

Conclusion
MFAP4 levels in plasma were associated with severity of COPD and were correlated to clinical characteristics of the emphysema phenotype.
Original languageEnglish
Publication date20. Jun 2012
Number of pages1
Publication statusPublished - 20. Jun 2012
EventCOPD8: An international Multidisciplinary Conference on Chronic Obstructive Pulmonary Disease - Birmingham, United Kingdom
Duration: 22. Jun 2012 → …

Conference

ConferenceCOPD8
CountryUnited Kingdom
CityBirmingham
Period22/06/2012 → …

Cite this

Johansson, S. L., Roberts, N. B., Schlosser, A., Johansson, H. W., Titlestad, I. L., Tornoe, I., ... Sørensen, G. L. (2012). Microfibril Associated Protein 4 (MFAP4) as a biomarker of emphysema. Poster session presented at COPD8, Birmingham, United Kingdom.
Johansson, Sofie Lock ; Roberts, Nassim Bazeghi ; Schlosser, Anders ; Johansson, Helle Wulf ; Titlestad, Ingrid Louise ; Tornoe, Ida ; Holmskov, Uffe ; Vestbo, Jørgen ; Sørensen, Grith Lykke. / Microfibril Associated Protein 4 (MFAP4) as a biomarker of emphysema. Poster session presented at COPD8, Birmingham, United Kingdom.1 p.
@conference{7ceb667ff62f4e4ca8b1ed962f9e32cf,
title = "Microfibril Associated Protein 4 (MFAP4) as a biomarker of emphysema",
abstract = "BackgroundTo enhance accuracy in evaluating prognosis and target therapy, there is a need for biomarkers in COPD. Yet, there are no reliable biomarkers that can differentiate between phenotypes of COPD. MFAP4 is a glycoprotein, co-localized with elastin and microfibrils in elastic fibres. We hypothesized that circulating MFAP4 reflects elastin degradation and thereby emphysema in COPD patients.MethodsPlasma levels of MFAP4 (pMFAP4) were determined by ELISA in 74 Danish COPD patients from the multicentre ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points) study. Associations between log-transformed pMFAP4 levels and clinical outcomes were assessed by multiple regression analysis. Age, gender and current smoking were included as covariates.ResultsLevels of pMFAP4 associated significantly with GOLD stages and were significantly higher in GOLD IV than in II. LogpMFAP4 was positively correlated to percentage of low attenuation area on HRCT (LAA{\%}) (β: 0.007, p<0.005). There was moreover a significant negative association between plasma logpMFAP4 and FEV1/FVC index (β:-0.007, p<0.05), reversibility (β:-0.6p<0.05). There was a significant interaction between gender and BMI and Fat Free Mass Index respective (FFMI), showing a significant negative association between MFAP4 and BMI (β:-0.03, p<0.01) and FFMI (β:-0.08, p<0.005) among women.ConclusionMFAP4 levels in plasma were associated with severity of COPD and were correlated to clinical characteristics of the emphysema phenotype.",
author = "Johansson, {Sofie Lock} and Roberts, {Nassim Bazeghi} and Anders Schlosser and Johansson, {Helle Wulf} and Titlestad, {Ingrid Louise} and Ida Tornoe and Uffe Holmskov and J{\o}rgen Vestbo and S{\o}rensen, {Grith Lykke}",
year = "2012",
month = "6",
day = "20",
language = "English",
note = "null ; Conference date: 22-06-2012",

}

Microfibril Associated Protein 4 (MFAP4) as a biomarker of emphysema. / Johansson, Sofie Lock; Roberts, Nassim Bazeghi; Schlosser, Anders; Johansson, Helle Wulf; Titlestad, Ingrid Louise; Tornoe, Ida ; Holmskov, Uffe; Vestbo, Jørgen; Sørensen, Grith Lykke.

2012. Poster session presented at COPD8, Birmingham, United Kingdom.

Research output: Contribution to conference without publisher/journalPosterResearchpeer-review

TY - CONF

T1 - Microfibril Associated Protein 4 (MFAP4) as a biomarker of emphysema

AU - Johansson, Sofie Lock

AU - Roberts, Nassim Bazeghi

AU - Schlosser, Anders

AU - Johansson, Helle Wulf

AU - Titlestad, Ingrid Louise

AU - Tornoe, Ida

AU - Holmskov, Uffe

AU - Vestbo, Jørgen

AU - Sørensen, Grith Lykke

PY - 2012/6/20

Y1 - 2012/6/20

N2 - BackgroundTo enhance accuracy in evaluating prognosis and target therapy, there is a need for biomarkers in COPD. Yet, there are no reliable biomarkers that can differentiate between phenotypes of COPD. MFAP4 is a glycoprotein, co-localized with elastin and microfibrils in elastic fibres. We hypothesized that circulating MFAP4 reflects elastin degradation and thereby emphysema in COPD patients.MethodsPlasma levels of MFAP4 (pMFAP4) were determined by ELISA in 74 Danish COPD patients from the multicentre ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points) study. Associations between log-transformed pMFAP4 levels and clinical outcomes were assessed by multiple regression analysis. Age, gender and current smoking were included as covariates.ResultsLevels of pMFAP4 associated significantly with GOLD stages and were significantly higher in GOLD IV than in II. LogpMFAP4 was positively correlated to percentage of low attenuation area on HRCT (LAA%) (β: 0.007, p<0.005). There was moreover a significant negative association between plasma logpMFAP4 and FEV1/FVC index (β:-0.007, p<0.05), reversibility (β:-0.6p<0.05). There was a significant interaction between gender and BMI and Fat Free Mass Index respective (FFMI), showing a significant negative association between MFAP4 and BMI (β:-0.03, p<0.01) and FFMI (β:-0.08, p<0.005) among women.ConclusionMFAP4 levels in plasma were associated with severity of COPD and were correlated to clinical characteristics of the emphysema phenotype.

AB - BackgroundTo enhance accuracy in evaluating prognosis and target therapy, there is a need for biomarkers in COPD. Yet, there are no reliable biomarkers that can differentiate between phenotypes of COPD. MFAP4 is a glycoprotein, co-localized with elastin and microfibrils in elastic fibres. We hypothesized that circulating MFAP4 reflects elastin degradation and thereby emphysema in COPD patients.MethodsPlasma levels of MFAP4 (pMFAP4) were determined by ELISA in 74 Danish COPD patients from the multicentre ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points) study. Associations between log-transformed pMFAP4 levels and clinical outcomes were assessed by multiple regression analysis. Age, gender and current smoking were included as covariates.ResultsLevels of pMFAP4 associated significantly with GOLD stages and were significantly higher in GOLD IV than in II. LogpMFAP4 was positively correlated to percentage of low attenuation area on HRCT (LAA%) (β: 0.007, p<0.005). There was moreover a significant negative association between plasma logpMFAP4 and FEV1/FVC index (β:-0.007, p<0.05), reversibility (β:-0.6p<0.05). There was a significant interaction between gender and BMI and Fat Free Mass Index respective (FFMI), showing a significant negative association between MFAP4 and BMI (β:-0.03, p<0.01) and FFMI (β:-0.08, p<0.005) among women.ConclusionMFAP4 levels in plasma were associated with severity of COPD and were correlated to clinical characteristics of the emphysema phenotype.

M3 - Poster

ER -

Johansson SL, Roberts NB, Schlosser A, Johansson HW, Titlestad IL, Tornoe I et al. Microfibril Associated Protein 4 (MFAP4) as a biomarker of emphysema. 2012. Poster session presented at COPD8, Birmingham, United Kingdom.